Skip to content

Heparin Dose and Post Operative Bleeding in Cardiopulmonary Bypass Patients

Heparin Dose and Post Operative Bleeding in Cardiopulmonary Bypass Patients

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01574105
Enrollment
66
Registered
2012-04-10
Start date
2012-05-31
Completion date
2013-01-31
Last updated
2014-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Disease

Keywords

Heparin Dose, Heparin Resistance, Chest Tube Losses, Transfusion Events

Brief summary

Blood is anticoagulated using a drug named heparin during open-heart surgery to allow it to safely pass through the heart-lung machine which pumps the blood throughout the body during the surgery. Each patient is given the heparin they need for their surgery. This means some patients receive more or less heparin than other patients. In this study, the investigators will be evaluating the current anticoagulation protocol for open heart surgery in use at the Royal University Hospital. The goal of this project is to compare patients who require and receive more heparin for proper anticoagulation to those patients who require and receive less heparin. Open-heart surgery will proceed according to the standard hospital protocol. All research participants will be treated according to standard post-open heart surgery protocol in the ICU. This will include measurement of blood loss by keeping track of chest tube outputs and administration of blood transfusions. This study focuses on Saskatoon Health Region patients having open heart surgery in terms of the protocol for anticoagulation and blood transfusions.

Detailed description

This study examines heparin doses of patients having cardiopulmonary bypass supported surgery in terms of their sensitivity and resistance to heparin which is the standard anticoagulant used. The investigators use the Heparin Management System, an analyser that performs a heparin dose response test. In this test, a patient's whole blood is mixed with increasing amounts of heparin to determine the required dose to achieve a set level of anticoagulation. Patients who are found to resistant to heparin and needing a higher dose are thought by some to bleed more post operatively. It is my view that when the patient is given the correct amount of heparin which is then reversed by the correct amount of protamine (the reversal agent) the bleeding is not determined by heparin dose. Hypothesis statement: Higher doses of heparin do not cause increased postoperative bleeding and transfusion events in the postoperative CPB patient. Purposes of the Study 1. Compare heparin sensitive and resistant patients in terms of postoperative bleeding and transfusion events. 2. Determine the incidence of heparin sensitivity or resistance in patients. 3. Identify preoperative factors that lead to heparin resistance or sensitivity in patients. 4. Using the Heparin Dose Response test in determining heparin resistant and sensitive patients. 5. Examination of anticoagulation protocol for open-heart surgery. 6. Effect of preoperative antiplatelet and anticoagulant therapy on perioperative care. 7. Use routine laboratory tests and values as well as common clinically available values in the conduct of the study so that results would be clinically relevant. This is a prospective observational study. Patients will be divided into two groups dependant upon the results of their heparin dose response test; sensitive or resistant. Two groups of thirty will be selected to achieve 90% power at the 0.025 level of significance using a one-sided two-sample t-test. The primary investigator will collect all data and submit the means to the statistician. Based on anecdotal experience the investigators expect there will be no difference between the two groups in terms of chest tube losses and transfusion events post-operatively. This work is quite relevant to the investigators daily practice. Every open heart patient is anticoagulated with heparin and bleeds post operatively. The investigators goal is a reproducibly safe anticoagulation level and an acceptable level of chest tube losses. This translates to getting patients out of the operating room in a timely fashion and minimizing transfusion events.

Interventions

None listed

Sponsors

University of Saskatchewan
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
40 Years to 85 Years
Healthy volunteers
Yes

Inclusion criteria

* Patients scheduled for elective or urgent CABG of two to six vessels.

Exclusion criteria

* Preoperative: * Hemoglobin of less than 110grams/Litre * Under 18 years of age * Mass less than 75 kilograms * Presence of an intra-aortic balloon pump * Emergency surgery, requiring operative intervention within 24 hours of consultation to the cardiac surgery team * Need for cardiac surgical intervention in addition to planned CABG (with the exception of patent foramen ovale closure) * Ejection fraction of less than 50%, as determined by echocardiogram or angiography * Pulmonary hypertension with pulmonary artery pressures greater than 60mmHg * Presence of infectious endocarditis * Hepatic failure with impaired liver function, including INR greater than 1.5 Known diagnosed bleeding disorder * History of heparin induced thrombocytopenia and thrombosis * Renal failure with pre-operative creatinine greater than 200ml/min or oliguria with urine output less than 10millilitres/hour * Allergy to tranexamic acid * Pregnancy Intraoperative: * Discovery of infectious endocarditis * Need for cardiac surgical intervention in addition to planned coronary CABG

Design outcomes

Primary

MeasureTime frameDescription
Chest Tube LossesChest tube losses are recorded from departure from operating room to chest tube removal in the ICU (normally less than 24 hrs)Chest tube losses will be measured in millilitres upon arrival in the Intensive Care unit (ICU) after six hours in the ICU and total chest tube losses during the ICU stay. Chest tube losses are the amount of blood collected in a graduated chest tube collection reservoir from chest tubes placed in the patient's chest wound at the end of surgery.

Secondary

MeasureTime frameDescription
Transfusion EventsData collection begins with patient arrival in the operating room and ends with discharge from the ICU (normally less than 24hrs)Transfusion events to recorded will be the number of patients receiving units of red blood cells, units of platelets, units of plasma and units of cryoprecipitate.

Countries

Canada

Participant flow

Recruitment details

Began May 1, 2012 Completed January 15, 2013 Patients identified in preadmission clinic or ward.

Pre-assignment details

Exclusion criteria included: renal failure, liver dysfunction, baseline INR \>1.5, clotting factor deficiencies, intra-aortic balloon pump therapy, emergency surgery, pregnancy, ejection fraction less than 50%, age less than 18 years, pulmonary hypertension infectious endocarditis, and history of heparin induced thrombocytopenia.

Participants by arm

ArmCount
Heparin Resistant
Patients whose heparin dose response slope was 89 sec/iu/ml or lower prior to surgery.
29
Heparin Sensitive
Patients whose heparin dose response slope was 90 sec/iu/ml or higher prior to surgery.
37
Total66

Baseline characteristics

CharacteristicHeparin SensitiveHeparin ResistantTotal
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
21 Participants18 Participants39 Participants
Age, Categorical
Between 18 and 65 years
16 Participants11 Participants27 Participants
Age, Continuous67.8 years
STANDARD_DEVIATION 9.4
67.4 years
STANDARD_DEVIATION 9.8
67.6 years
STANDARD_DEVIATION 9.5
Region of Enrollment
Canada
37 participants29 participants66 participants
Sex: Female, Male
Female
5 Participants3 Participants8 Participants
Sex: Female, Male
Male
32 Participants26 Participants58 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
0 / 290 / 37
serious
Total, serious adverse events
0 / 290 / 37

Outcome results

Primary

Chest Tube Losses

Chest tube losses will be measured in millilitres upon arrival in the Intensive Care unit (ICU) after six hours in the ICU and total chest tube losses during the ICU stay. Chest tube losses are the amount of blood collected in a graduated chest tube collection reservoir from chest tubes placed in the patient's chest wound at the end of surgery.

Time frame: Chest tube losses are recorded from departure from operating room to chest tube removal in the ICU (normally less than 24 hrs)

ArmMeasureValue (MEAN)Dispersion
Heparin ResistantChest Tube Losses726 milliltersStandard Deviation 371
Heparin SensitiveChest Tube Losses781 milliltersStandard Deviation 320
Comparison: For the analysis of the patient characteristics Wilcoxon, Chi-square and Fischer's exact tests were used. An upper bound of a two-sided 95% confidence interval (CI) of the mean difference between resistant and sensitive groups for all values of chest tube losses was computed by analysis of covariance (ANCOVA), and compared with pre-specified noninferiority limits. Covariates in the ANCOVA model included patient characteristics differing between two groups with a p-value \<0.1.p-value: <0.1ANCOVA
Secondary

Transfusion Events

Transfusion events to recorded will be the number of patients receiving units of red blood cells, units of platelets, units of plasma and units of cryoprecipitate.

Time frame: Data collection begins with patient arrival in the operating room and ends with discharge from the ICU (normally less than 24hrs)

ArmMeasureValue (NUMBER)
Heparin ResistantTransfusion Events4 Participants
Heparin SensitiveTransfusion Events16 Participants

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026